Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.
about
Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives.Cancer Immunotherapies: Are They as Effective in the Elderly?A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma.The efficacy and safety of adjuvant interferon-alfa therapy in the evolving treatment landscape for resected high-risk melanoma.Checkpoint inhibitors in melanoma and early phase development in solid tumors: what's the future?Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.Immune Checkpoint Inhibitors in Melanoma and HIV Infection.Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells.Intratumoral immunotherapy: using the tumor as the remedy.Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives.Trial watch: Immune checkpoint blockers for cancer therapy.Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.CD4 and CD8 T lymphocyte interplay in controlling tumor growth.Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management.Safety of shortened infusion times for combined ipilimumab and nivolumab.Cell death-based treatments of melanoma:conventional treatments and new therapeutic strategies.Ipilimumab induced digital vasculitis.Immunotherapy in managing metastatic melanoma: which treatment when?The Great Debate at "Melanoma Bridge", Napoli, December 2nd, 2017.Clinical Development of PD-1 in Advanced Melanoma.PD-L1 inhibitors in the pipeline: Promise and progress.Clinical assessment of immune-related adverse events.Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab.Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in CancerPharmacometric Applications and Challenges in the Development of Therapeutic Antibodies in Immuno-OncologyNeoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoireDose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors
P2860
Q33819820-FD2475C9-5618-49C2-BEDB-896ED8F18D48Q38679662-1AC8CDFC-50FC-48C7-92E0-219DBAD32491Q38726713-31039E09-0C62-4161-9970-D7194576314CQ39382600-41B70996-60C8-4634-A2F7-6BDC7B05DE43Q42343743-4FC28CBB-AF01-4891-8C26-14343B520654Q47102520-18A92400-AC88-4EAD-93C9-8D49CF2B8D87Q47138765-92FF8DD8-9D62-4121-B281-205A1A5C6061Q47227422-E1E66730-A6C5-43ED-BE05-7AE91326CAE8Q47281370-281E2CC4-1C47-4231-BF46-9B1ADEA6993DQ47375181-C8C8C14D-479D-4622-BAD4-8A3ABB73FF22Q47393365-98D941A3-C1E0-477C-A2CE-F30E7C6EF653Q47705923-1599BF47-541E-4F3B-82E4-287A2CD593A6Q48185876-C6734C7A-95B0-41F6-A63C-A87D3A73C3B7Q48289680-C8928F64-3A21-42A9-966C-8BA7E5266541Q49501208-20557310-9C2F-4CDA-9874-6C4E1FCB256CQ49679681-6205C1DF-55EB-41E7-8573-811C1CAC1808Q50057704-F9238367-30C6-4A32-8389-EEA7BD8E3B1FQ50166276-1570CFD7-9898-4057-9771-6BBD33D25213Q52582484-DAA60293-C3CF-4F62-AD48-AB0164BD5BB8Q52707889-29174DEE-1EA5-4B30-8ACF-238C5DCAE1C0Q52731766-102FF276-6BD6-4763-95EF-A35CB51EA334Q55292659-62860ACF-54F4-457B-855B-2A528B63A749Q55342245-7DA2666A-4ABC-4E78-98EE-C06817C8F8A1Q56891212-7CB84E83-AE1E-480A-936F-726CB7206D3AQ57495826-3F2F8A3B-9819-435A-ADEC-0ADBBA545DB8Q57797941-E7609FFE-F684-4033-B120-C10DF74993CFQ58698379-663AC7E4-DF4C-47C0-8DD1-5182FC9BEACE
P2860
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Ipilimumab 10 mg/kg versus ipi ...... d, multicentre, phase 3 trial.
@en
Ipilimumab 10 mg/kg versus ipi ...... d, multicentre, phase 3 trial.
@nl
type
label
Ipilimumab 10 mg/kg versus ipi ...... d, multicentre, phase 3 trial.
@en
Ipilimumab 10 mg/kg versus ipi ...... d, multicentre, phase 3 trial.
@nl
prefLabel
Ipilimumab 10 mg/kg versus ipi ...... d, multicentre, phase 3 trial.
@en
Ipilimumab 10 mg/kg versus ipi ...... d, multicentre, phase 3 trial.
@nl
P2093
P50
P1433
P1476
Ipilimumab 10 mg/kg versus ipi ...... d, multicentre, phase 3 trial.
@en
P2093
Andrzej Mackiewicz
Anila Qureshi
Brigitte Dreno
Carmen Loquai
Caroline Robert
Catriona McNeil
Christoph Hoeller
Claus Garbe
Céleste Lebbé
Delphine Hennicken
P304
P356
10.1016/S1470-2045(17)30231-0
P50
P577
2017-03-27T00:00:00Z